Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Lineage Therap ( (LCTX) ) has provided an announcement.
On June 26, 2025, Lineage Therap held its Annual Meeting, where shareholders elected seven directors to the board, ratified the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, approved executive compensation on an advisory basis, and approved an EIP Amendment. These decisions reflect shareholder support for the company’s current leadership and strategic direction, potentially impacting its governance and financial practices.
The most recent analyst rating on (LCTX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Lineage Therap stock, see the LCTX Stock Forecast page.
Spark’s Take on LCTX Stock
According to Spark, TipRanks’ AI Analyst, LCTX is a Neutral.
Lineage Cell Therapeutics exhibits strengths in technical analysis and promising earnings call developments, particularly in key programs like OpRegen and OPC1. However, financial and valuation challenges typical of biotech firms weigh down the score, with negative profitability and reliance on external funding posing risks.
To see Spark’s full report on LCTX stock, click here.
More about Lineage Therap
Average Trading Volume: 2,202,714
Technical Sentiment Signal: Hold
Current Market Cap: $205M
See more insights into LCTX stock on TipRanks’ Stock Analysis page.